Canadian Cancer Society and Prostate Cancer Canada celebrate their amalgamation
February 3, 2020 (Toronto, ON) – On the eve of World Cancer Day, the Canadian Cancer Society (CCS) and Prostate Cancer Canada (PCC) have finalized their amalgamation. This transformational partnership is a bold and critically needed step forward within the cancer charity sector in Canada. The newly amalgamated organization will be led by Andrea Seale, CEO of CCS.
Canadian Cancer Society and Prostate Cancer Canada celebrate their amalgamation
February 3, 2020 (Toronto, ON) – On the eve of World Cancer Day, the Canadian Cancer Society (CCS) and Prostate Cancer Canada (PCC) have finalized their amalgamation. This transformational partnership is a bold and critically needed step forward within the cancer charity sector in Canada. The newly amalgamated organization will be led by Andrea Seale, CEO of CCS.
Prostate Cancer Canada and the Canadian Cancer Society agree to amalgamate
Toronto. December 12, 2019 – Prostate Cancer Canada and the Canadian Cancer Society (CCS) are excited to announce their intention to embark upon a strategic amalgamation that will strengthen and support cancer research, education and the needs of Canadians and their families dealing with the disease. As part of the agreement, Prostate Cancer Canada’s activities and initiatives will remain an important part of the Canadian Cancer Society.
1.5 million Canadian men over 50 now at unnecessary risk for prostate cancer
Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.5 million Canadian men 50+ are not seeking early prostate cancer testing through the prostate specific antigen (PSA) blood test. The survey, Men At Risk: The Prostate Cancer Testing Gap, shows while awareness about the importance of early detection is high, Canadian men 50+ are reluctant to be tested.
Prostate Cancer Canada and the Movember Foundation Announce $4M in Research Grants
Toronto, October 23, 2018 – Prostate Cancer Canada and the Movember Foundation today announced $4 million in funding to three Canadian researchers to predict how well prostate cancer will respond to treatment, based on men’s biological markers, specifically in their tumour cells and blood – opening a path to more personalized care with fewer side effects and a better chance of survival. The grants have been awarded to Dr. Tarek Bismar from the University of Calgary, Dr. Hansen He from University Health Network and Dr. Kim Chi from BC Cancer. This research aims to determine how we can use a man’s tumour biology to offer better care to men at three critical stages of their prostate cancer journey.
Prostate Cancer Canada launches first national program in radioligand therapy
Toronto, June 27, 2018 – Canadian researchers are leading the future of treatment for men with advanced prostate cancer in this country, with a new Prostate Cancer Canada grant funded by the Movember Foundation. The National Program on Targeted Radionuclide Therapy for Prostate Cancer focuses on radioligand therapy (RLT): a new form of treatment for men with advanced prostate cancer which cannot be cured by current methods. This coordinated, national initiative aims to accelerate access to this promising and innovative treatment for Canadian men.
Honouring dad this Father’s Day the Canadian way: In plaid
TORONTO, ON – (May 8, 2018) – Plaid replaces business-casual on Friday, June 15 as hundreds of thousands of Canadians don the iconic Canadian attire all to honour dad and end prostate cancer. The nationwide Prostate Cancer Canada fundraiser and awareness campaign sees scores of workplaces and individuals changing the lives of the one in seven Canadian men who will be diagnosed with the disease.